Table 3 Demographics and salivary secretion rates for patients selected for mucin O-glycosylation analysis
From: Stimulated saliva composition in patients with cancer of the head and neck region
Code | Sex | Age | Tumor site | TNM, stage | Treatment | Stimulated salivary secretion rate (ml/min) | |||
|---|---|---|---|---|---|---|---|---|---|
Pretreat | 6 mo | 1 year | 2 years | ||||||
1 | M | 55 | Tumor colli | T0N2M0, st IV | S, ERT | 2.4 | 0.5 | 0.8 | 1.1 |
2 | M | 65 | Tonsil | T2N1M0, st II | C, ERT | 2.3 | 0.7 | 1.9 | 1.6 |
3 | F | 47 | Tonsil | T2N0M0, st II | ERT | 1.9 | 0.7 | 0.6 | 1.0 |
4 | M | 43 | Nasopharynx | T3N2M0, st III | C, ERT | 2.4 | 0.7 | 1.0 | 1.0 |
5 | F | 66 | Tonsil | T2N2M0, st IV | C, ERT | 1.6 | 0.3 | 0.8 | 0.7 |
6 | M | 54 | Tonsil | T2N2bM0, st IV | C, ERT | 0.9 | 0.3 | 0.3 | 0.5 |